IRIS - Res&Arch Institutional Research Information System - Research & Archive

CHIASSERINI, DAVIDE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.102
AS - Asia 2.618
EU - Europa 2.253
SA - Sud America 487
AF - Africa 61
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 5
Totale 8.532
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.034
SG - Singapore 1.255
IT - Italia 468
IE - Irlanda 423
BR - Brasile 384
CN - Cina 381
HK - Hong Kong 337
RU - Federazione Russa 301
VN - Vietnam 246
FR - Francia 198
DE - Germania 197
UA - Ucraina 157
SE - Svezia 119
FI - Finlandia 118
KR - Corea 84
GB - Regno Unito 64
IN - India 53
RO - Romania 47
TR - Turchia 44
IQ - Iraq 40
AR - Argentina 37
CA - Canada 36
BD - Bangladesh 35
AT - Austria 29
NL - Olanda 29
PL - Polonia 20
CH - Svizzera 19
ZA - Sudafrica 19
JP - Giappone 18
SA - Arabia Saudita 18
VE - Venezuela 18
MX - Messico 17
ES - Italia 16
ID - Indonesia 16
PK - Pakistan 16
CL - Cile 14
CZ - Repubblica Ceca 12
EC - Ecuador 12
UZ - Uzbekistan 12
BE - Belgio 11
CO - Colombia 9
KE - Kenya 8
AE - Emirati Arabi Uniti 7
JO - Giordania 7
MY - Malesia 7
TN - Tunisia 7
LB - Libano 6
MA - Marocco 6
AO - Angola 5
IL - Israele 5
PH - Filippine 5
PY - Paraguay 5
DZ - Algeria 4
GR - Grecia 4
NP - Nepal 4
AZ - Azerbaigian 3
BO - Bolivia 3
CR - Costa Rica 3
DK - Danimarca 3
KZ - Kazakistan 3
LT - Lituania 3
PA - Panama 3
SK - Slovacchia (Repubblica Slovacca) 3
TH - Thailandia 3
BA - Bosnia-Erzegovina 2
BG - Bulgaria 2
CG - Congo 2
DO - Repubblica Dominicana 2
ET - Etiopia 2
EU - Europa 2
GT - Guatemala 2
OM - Oman 2
PE - Perù 2
PS - Palestinian Territory 2
TJ - Tagikistan 2
TW - Taiwan 2
UY - Uruguay 2
XK - ???statistics.table.value.countryCode.XK??? 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
AM - Armenia 1
AU - Australia 1
BH - Bahrain 1
BW - Botswana 1
BZ - Belize 1
CI - Costa d'Avorio 1
CY - Cipro 1
FJ - Figi 1
GA - Gabon 1
GY - Guiana 1
HN - Honduras 1
HR - Croazia 1
HT - Haiti 1
HU - Ungheria 1
IR - Iran 1
KG - Kirghizistan 1
KI - Kiribati 1
LU - Lussemburgo 1
LV - Lettonia 1
LY - Libia 1
Totale 8.520
Salva come PNG Salva come JPEG
Città #
Singapore 950
Dublin 421
Chandler 414
Hong Kong 337
San Jose 298
Ashburn 219
Perugia 213
San Mateo 183
Boardman 152
Moscow 132
Santa Clara 129
Beijing 116
Altamura 93
Lauterbourg 89
Seoul 83
Medford 81
Princeton 81
Munich 78
Jacksonville 74
Los Angeles 72
Ho Chi Minh City 71
Wilmington 70
Lawrence 68
The Dalles 62
Dong Ket 59
New York 48
Des Moines 39
Hanoi 38
Bucharest 34
Andover 31
Piscataway 29
Frankfurt am Main 28
São Paulo 28
Turku 28
Ann Arbor 27
Helsinki 22
Redmond 22
Chennai 21
Dallas 21
Denver 20
Izmir 19
Brooklyn 18
Orem 18
San Paolo di Civitate 18
Tokyo 18
Nuremberg 17
Council Bluffs 16
Rome 16
Johannesburg 15
Saint Petersburg 15
Warsaw 15
Baghdad 14
Phoenix 14
Vienna 14
Amsterdam 13
Stockholm 13
Guangzhou 11
Lappeenranta 11
London 11
Milan 11
Montreal 11
Belo Horizonte 10
Brussels 10
Chicago 10
Falkenstein 10
Hefei 10
Houston 10
Istanbul 10
Norwalk 10
Saint Louis 10
Boston 9
Manchester 9
Shanghai 9
Tashkent 9
Columbus 8
Florence 8
Olomouc 8
Riyadh 8
Amman 7
Atlanta 7
Brasília 7
Caracas 7
Changsha 7
Curitiba 7
Dhaka 7
Nairobi 7
Poplar 7
São José dos Campos 7
Toronto 7
Campinas 6
Charlotte 6
Da Nang 6
Falls Church 6
Măgurele 6
Redwood City 6
Rio de Janeiro 6
Santiago 6
Seattle 6
Terni 6
Ankara 5
Totale 5.589
Salva come PNG Salva come JPEG
Nome #
Alpha-synuclein targets GluN2A NMDA receptor subunit causing striatal synaptic dysfunction and visuospatial memory alteration 169
Analisi del proteoma di carcinomi papillari della tiroide positivi per la mutazione BRAFV600E 144
Changes in CSF acetyl- and butyrylcholinesterase activity after long-term treatment with AChE inhibitors in Alzheimer's disease. 132
Cerebrospinal fluid β-glucocerebrosidase activity is reduced in parkinson's disease patients 132
Characterization of Brain Lysosomal Activities in GBA-Related and Sporadic Parkinson’s Disease and Dementia with Lewy Bodies 130
3-Bromopyruvate treatment induces alterations of metabolic and stress-related pathways in glioblastoma cells 129
Selective loss of glucocerebrosidase activity in sporadic Parkinson's disease and dementia with Lewy bodies 123
Protein expression changes induced in murine peritoneal macrophages by Group B Streptococcus 122
Cerebrospinal fluid biomarkers in Parkinson disease. 121
The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. 119
Effects of central and peripheral inflammation on hippocampal synaptic plasticity 119
Cerebrospinal fluid lysosomal enzymes and α-synuclein in Parkinson's disease. 119
Performance of Aβ1-40, Aβ1-42, Total Tau, and Phosphorylated Tau as Predictors of Dementia in a Cohort of Patients with Mild Cognitive Impairment. 117
Persistent activation of microglia and NADPH drive hippocampal dysfunction in experimental multiple sclerosis 113
Diagnostic utility of cerebrospinal fluid α-synuclein in Parkinson's disease: A systematic review and meta-analysis 113
Crosstalk between long-term sublethal oxidative stress and detrimental inflammation as potential drivers for age-related retinal degeneration 113
Interleukin-17 affects synaptic plasticity and cognition in an experimental model of multiple sclerosis 113
Cerebrospinal fluid hemoglobin levels as markers of blood contamination: relevance for α-synuclein measurement 112
Cerebrospinal fluid biomarkers for the diagnosis and prognosis of Parkinson's disease: protocol for a systematic review and individual participant data meta-analysis 111
Identification of differentially expressed proteins in papillary thyroid carcinomas with V600E mutation of BRAF 109
Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementias. 109
Cytoskeletal perturbation leads to platelet dysfunction and thrombocytopenia in variant forms of Glanzmann thrombasthenia 109
Changes in endolysosomal enzyme activities in cerebrospinal fluid of patients with Parkinson's disease. 107
Proteomic analysis of papillary thyroid carcinoma reveals demodulation of mechanisms regulating cell proliferation, susceptibility to oxidative stress and cellular aggregation 103
Lysosomal enzyme activities in human brain 101
Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia 101
Fingerprinting Alzheimer's Disease by 1H Nuclear Magnetic Resonance Spectroscopy of Cerebrospinal Fluid 100
L’analisi proteomica del carcinoma papillare della tiroide evidenzia modificazioni dello stato ossidoriduttivo e della struttura delle cellule tumorali 99
Extracellular Vesicles in Aging: An Emerging Hallmark? 98
Mitochondria and the link between neuroinflammation and neurodegeneration. 97
Performance Evaluation of an Automated ELISA System for Alzheimer's Disease Detection in Clinical Routine 96
Characterization of Two Populations of Prostasomes by Proteomics and Dynamic Light Scattering 95
Comparison of Different Matrices as Potential Quality Control Samples for Neurochemical Dementia Diagnostics 95
CSF Biomarkers in Parkinson's disease 93
Measurement of CSF core Alzheimer disease biomarkers for routine clinical diagnosis: Do fresh vs frozen samples differ? 93
CSF levels of heart fatty acid binding protein are altered during early phases of Alzheimer's disease. 92
Biomarkers in Parkinson's disease: From pathophysiology to early diagnosis 92
Identification and Partial Characterization of Two Populations of Prostasomes by a Combination of Dynamic Light Scattering and Proteomic Analysis 90
Erratum: Persistent activation of microglia and NADPH oxidase drive hippocampal dysfunction in experimental multiple sclerosis (Scientific Reports (2016) 6 (20926) DOI: 10.1038/srep20926) 89
Standardization and harmonization of distributed multi-center proteotype analysis supporting precision medicine studies 89
Role of FABP3 as biomarker in Alzheimer's disease and synucleinopathies 87
Diagnostic utility of CSF α-synuclein species in Parkinson's disease: Protocol for a systematic review and meta-analysis 86
Role of CSF biomarkers in the diagnosis of prodromal Alzheimer's disease. 84
A Practical Guide to Immunoassay Method Validation 84
Differential protein expression in glioblastoma cells induced by 3-bromopyruvate 83
A prostate cancer proteomics database for swath-ms based protein quantification 83
Sistema immunitario e cefalee primarie 82
Origin of α-mannosidase activity in CSF 82
Molecular characterization of colorectal adenomas reveals POFUT1 as a candidate driver of tumor progression 81
C1q is increased in cerebrospinal fluid-derived extracellular vesicles in Alzheimer's disease: A multi-cohort proteomics and immuno-assay validation study 80
Proteomic biomarkers for the detection of endometrial cancer 80
HOPS/TMUB1 Enhances Apoptosis in TP53 Mutation-Independent Setting in Human Cancers 79
Proteomic analysis of papillary thyroid carcinomas reveals demodulation of signal transduction pathways, increased resistance to oxidative stress and gain of invasive phenotype. 78
Role of Lysosomal Enzymes in Parkinson’s Disease: Lesson from Gaucher’s Disease 78
Lysosomal enzymes in PD: further evidence is needed. 78
Factors influencing the measurement of lysosomal enzymes activity in human cerebrospinal fluid. 78
CSF proteome analysis in multiple sclerosis patients by two-dimensional electrophoresis. 78
Fibroblast growth factor-2 levels are elevated in the cerebrospinal fluid of multiple sclerosis patients. 77
Proteomic changes induced by Group B Streptococcus in mouse peritoneal macrophages 77
Molecular dynamic simulation of the catalytic domain of BRAF in response to activating and inactivating mutation 76
Validation of microRNAs in Cerebrospinal Fluid as Biomarkers for Different Forms of Dementia in a Multicenter Study 76
Investigating alpha-synuclein co-pathology in Alzheimer's disease by means of cerebrospinal fluid alpha-synuclein seed amplification assay 75
Differential role of CSF alpha-synuclein species, tau, and Aβ42 in Parkinson's Disease. 75
Longitudinal changes in CSF alpha-synuclein species reflect Parkinson's disease progression 75
Comprehensive library generation for identification and quantification of endometrial cancer protein biomarkers in cervico-vaginal fluid 75
Cerebrospinal fluid lipoproteins inhibit α-synuclein aggregation by interacting with oligomeric species in seed amplification assays 74
Mortalin Inhibition in Experimental Parkinson's Disease 74
Expression of ionotropic glutamate receptor GLUR3 and effects of glutamate on MBP- and MOG-specific lymphocyte activation and chemotactic migration in multiple sclerosis patients. 73
Lysosomal Dysfunction and α-Synuclein Aggregation in Parkinson's Disease: Diagnostic Links 72
Italian consensus recommendations for a biomarker-based aetiological diagnosis in mild cognitive impairment patients 72
Structural dynamics shape the fitness window of alanine:glyoxylate aminotransferase 71
Potential diagnostic value of CSF metabolism-related proteins across the Alzheimer's disease continuum 71
Trajectories of CSF and plasma biomarkers across Alzheimer's disease continuum: Disease staging by NF-L, p-tau181, and GFAP 71
Urinary Biomarkers and Their Potential for the Non-Invasive Detection of Endometrial Cancer 71
Immunological profile of silent brain infarction and lacunar stroke. 69
Proteomic analysis of cerebrospinal fluid extracellular vesicles: A comprehensive dataset 69
PROTEOMIC ANALYSIS OF EXTRACELLULAR VESICLES IN ALZHEIMER’S DISEASE CEREBROSPINAL FLUID 68
Phosphatidylethanolamine Binding Protein 1 (PEBP1) in Alzheimer's Disease: ELISA Development and Clinical Validation 66
No diurnal variation of classical and candidate biomarkers of Alzheimer's disease in CSF 63
Modelli sperimentali 62
Validation of a quantitative cerebrospinal fluid alpha-synuclein assay in a European-wide interlaboratory study 62
The use of missing values in proteomic data-independent acquisition mass spectrometry to enable disease activity discrimination 61
Immunoassay detection of multiphosphorylated tau proteoforms as cerebrospinal fluid and plasma Alzheimer’s disease biomarkers 59
Quantitative SWATH-based proteomic profiling of urine for the identification of endometrial cancer biomarkers in symptomatic women 59
Methods to discover and validate biofluid-based biomarkers in neurodegenerative dementias 58
CSF neurosecretory proteins VGF and neuroserpin in patients with Alzheimer's and Lewy body diseases 58
Evidence for Elevated Cerebrospinal Fluid ERK1/2 Levels in Alzheimer Dementia. 58
Donor natural killer cells trigger production of beta-2-microglobulin to enhance post bone marrow transplant immunity 57
Required improvements for cerebrospinal fluid-based biomarker tests of Alzheimer's disease 56
Interferon-β1a protects neurons against mitochondrial toxicity via modulation of STAT1 signaling: electrophysiological evidence. 56
Fully automated measurement of plasma Aβ42/40 and p-tau181: Analytical robustness and concordance with cerebrospinal fluid profile along the Alzheimer's disease continuum in two independent cohorts 55
Non-Phosphorylated Tau as a Potential Biomarker of Alzheimer's Disease: Analytical and Diagnostic Characterization 55
Machine Learning Driven Profiling of Cerebrospinal Fluid Core Biomarkers in Alzheimer's Disease and Other Neurological Disorders 54
The Clinical Use of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease Diagnosis: The Italian Selfie 54
CSF and plasma Aβ42/40 across Alzheimer's disease continuum: comparison of two ultrasensitive Simoa® assays targeting distinct amyloid regions 53
Enhancing mummy ‘palaeobiographies’ though the use of multidisciplinary techniques and approaches 52
Biochemical Studies on Human Ornithine Aminotransferase Support a Cell-Based Enzyme Replacement Therapy in the Gyrate Atrophy of the Choroid and Retina 52
Kidney Fibrosis and Oxidative Stress: From Molecular Pathways to New Pharmacological Opportunities 48
Preanalytical Confounding Factors in the Analysis of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: The Issue of Diurnal Variation 48
Detection of endometrial cancer in cervico-vaginal fluid and blood plasma: leveraging proteomics and machine learning for biomarker discovery 47
Totale 8.543
Salva come PNG Salva come JPEG
Categoria #
all - tutte 38.573
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 38.573
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021114 0 0 0 0 0 0 0 0 0 17 30 67
2021/2022717 8 124 15 30 9 9 4 193 45 47 102 131
2022/20231.391 87 272 16 118 96 141 3 67 535 3 38 15
2023/2024613 32 65 45 17 8 4 113 33 70 22 94 110
2024/20251.625 30 137 59 77 219 104 72 130 297 90 276 134
2025/20263.409 226 247 214 481 491 309 627 190 355 269 0 0
Totale 8.805